RxDoctor Payments Data

Gretel Spitzer, MD

Family Medicine · Amherst, VANPI 1811334899

Payments from drug & device makers

$1,022in general payments, 2019–2025

Across 42 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$256
  • Lilly USA, LLC$157
  • Neurocrine Biosciences, Inc.$119
  • Pfizer$117
  • Astellas Pharma US Inc$113
  • Corcept Therapeutics$57
  • plus $202 from 8 others

What the payments were for

  • Food & beverage$97796%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,022 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$154,015
Medicare patients
347
Services billed
10,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$109,178
RexultiBrexpiprazole27$44,014
MounjaroTirzepatide30$34,324
EliquisApixaban34$32,021
XareltoRivaroxaban21$23,074
JanuviaSitagliptin Phosphate11$14,555
Spiriva HandihalerTiotropium Bromide16$13,274
SymbicortBudesonide/Formoterol Fumarate12$7,752
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$7,014
Epinephrine15$3,695
Omeprazole269$3,416
Levemir FlexpenInsulin Detemir12$3,174
Venlafaxine Hcl ErVenlafaxine Hcl88$2,883
Albuterol Sulfate HfaAlbuterol Sulfate148$2,749
Advair DiskusFluticasone Propion/Salmeterol12$2,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$256$109,17871 claims
Otsuka America Pharmaceutical, Inc.Rexulti$29$44,01427 claims
Lilly USA, LLCMounjaro$157$34,32430 claims
PfizerEliquis$117$32,02134 claims
AstraZenecaSymbicort$29$7,75212 claims
AbbVieSynthroid$42$1,84230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Amherst

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →